A Strategic Turn from Obesity to Cancer

When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but also lead a strategic shift from an increasingly crowded area of metabolic disease to focus on its experimental therapy for chronic myeloid leukemia. The company’s allosteric BCR-ABL inhibitor binds to a different site on the fusion protein than most first- and second-generation tyrosine kinase inhibitors. The data have the company and its investors believing the drug can reset the bar for both efficacy and tolerability in a multibillion-dollar market. We spoke with Burroughs about reinventing the company, the decision to seek partners for non-core assets, and how she is charting a clear path toward a broader oncology future.

You can listen to A Strategic Turn from Obesity to Cancer online on Radio and Podcast. Open the player on this page to stream the available audio.

A Strategic Turn from Obesity to Cancer is an episode from The Bio Report by Levine Media Group.

This episode is 22:53 long.

This episode was published on Feb 18, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.